{"orpha":98293,"name":"Hodgkin lymphoma","type":"Clinical group","group":"Group of disorders","status":"active","flags":[],"synonyms":[],"definition":"Hodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases.","note":null,"url":"https://raremap.alftech.space/d/ORPHA-98293/","orphanet_url":"https://www.orpha.net/en/disease/detail/98293","names":{"fr":{"name":"Lymphome de Hodgkin","synonyms":["Maladie de Hodgkin"],"definition":"Le lymphome de Hodgkin (LH) est un groupe hétérogène de néoplasies lymphatiques malignes des cellules B caractérisé sur le plan histologique par la présence de cellules de Hodgkin et de Reed-Sternberg dans la grande majorité des cas."},"de":{"name":"Hodgkin-Lymphom","synonyms":["Hodgkin-Krankheit"],"definition":"Das Hodgkin-Lymphom (HL) ist eine heterogene Gruppe maligner lymphoider Neoplasien mit B-Zell-Herkunft. In den meisten Fällen ist es histologisch durch Hodgkin und Reed-Sternberg (HRS)-Zellen gekennzeichnet."},"es":{"name":"Linfoma de Hodgkin","synonyms":["Enfermedad de Hodgkin"],"definition":"El linfoma de Hodgkin (HL) es un grupo heterogéneo de neoplasias linfoides malignas de origen en células B que se caracteriza histológicamente por la presencia de células de Hodgkin y de Reed-Sternberg (HRS) en la gran mayoría de los casos."},"it":{"name":"Linfoma di Hodgkin","synonyms":["Malattia di Hodgkin"],"definition":"Il linfoma di Hodgkin (HL) comprende un gruppo eterogeneo di neoplasie linfoidi maligne che originano nelle cellule B, che è caratterizzato ,istologicamente, dalla presenza di cellule di Hodgkin e di Reed-Sternberg (HRS) nella stragrande maggioranza dei casi."},"nl":{"name":"Hodgkin-lymfoom","synonyms":["Lymfoom van Hodgkin","Ziekte van Hodgkin"],"definition":"Hodgkin-lymfoom (HL) is een heterogene groep van maligne lymfoïde neoplasmata afkomstig van B-cellen, histologisch gekenmerkt door de aanwezigheid van Hodgkin en Reed-Sternberg (HRS)-cellen in de overgrote meerderheid van de gevallen."},"pt":{"name":"Linfoma de Hodgkin"},"pl":{"name":"Chłoniak Hodgkina","synonyms":["Chłoniak Hodgkina","Choroba Hodgkina"]},"cs":{"name":"Hodgkinův lymfom","synonyms":["Hodgkinova nemoc"]},"uk":{"name":"Лімфома Ходжкіна","definition":"Hodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases."},"zh":{"name":"霍奇金淋巴瘤","definition":"霍奇金淋巴瘤(HL)是一组起源于B细胞的异质性恶性淋巴肿瘤，在组织学上以Hodgkin和Reed-Sternberg(HRS)细胞的存在为特征，在绝大多数病例中表现为霍奇金细胞和里德-斯特恩伯格(Reed-Sternberg，HRS)细胞。"},"tr":{"name":"Hodgkin lenfoma"}},"xrefs":[{"source":"ICD-11","code":"2B30","qualifier":"E","icd_relation":"specific","validated":true,"icd11_uri":"1528863768"},{"source":"MONDO","code":"0004952","qualifier":"E","icd_relation":null,"validated":true},{"source":"MONDO","code":"4952","qualifier":"E","icd_relation":null,"validated":true},{"source":"MeSH","code":"D006689","qualifier":"E","icd_relation":null,"validated":true},{"source":"UMLS","code":"C0019829","qualifier":"E","icd_relation":null,"validated":true},{"source":"GARD","code":"2714","qualifier":"E","icd_relation":null,"validated":true},{"source":"MedDRA","code":"10020206","qualifier":"E","icd_relation":null,"validated":true}],"associations":[],"incoming_associations":[],"preferential_parent":{"orpha":250908,"name":"Rare neoplastic disease"},"parents":[{"orpha":289644,"name":"Epstein-Barr virus-associated malignant lymphoproliferative disorder","classifications":[202]},{"orpha":223735,"name":"Lymphoma","classifications":[194,202,233]}],"children":[{"orpha":391,"name":"Classic Hodgkin lymphoma","type":"Disease"},{"orpha":86893,"name":"Nodular lymphocyte predominant Hodgkin lymphoma","type":"Disease"}],"genes":[],"genes_via_subtypes":[],"inheritance":["Multigenic/multifactorial"],"onset":["Adolescent","Adult","Childhood","Elderly","Infancy"],"prevalence":[{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":2.4,"area":"Europe","status":"Validated","source":"RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Lifetime Prevalence","qualification":"Value and class","class":"1-5 / 10 000","value":46.9,"area":"Europe","status":"Validated","source":"22033323[PMID]_RARECARE surveillance of rare cancers in Europe[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":2.8,"area":"United States","status":"Validated","source":"National Cancer OTHERitute 2008[OTHER]_22835602[PMID]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 1 000 000","value":0.25,"area":"Japan","status":"Not yet validated","source":"emedicine[OTHER]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 1 000 000","value":0.25,"area":"China","status":"Not yet validated","source":"emedicine[OTHER]"}],"phenotypes":null}